Table 2 Summary of included studies by treatments according to HBeAg status
Treatments included in the network meta-analysis | Studies (n) | DB RCT (n) | Patients (n) | Publication years |
|---|---|---|---|---|
HBeAg-positive patients | ||||
Lamivudine (LAM) | 12 | 9 | 1925 | 1998–2015 |
Adefovir (ADV) | 6 | 3 | 652 | 2003–2015 |
Telbivudine (TBV) | 4 | 3 | 692 | 2005–2014 |
Entecavir (ETV) | 9 | 3 | 1127 | 2006–2017 |
Tenofovir disoproxil fumarate (TDF) | 6 | 4 | 1065 | 2008–2017 |
Tenofovir alafenamide (TAF) | 1 | 1 | 581 | 2016 |
Pegylated interferon (PEG-IFN) | 6 | 2 | 727 | 2005–2016 |
Combination therapies | 14 | 4 | 1740 | 2005–2016 |
Placebo (PLA) | 4 | 3 | 330 | 1998–2014 |
Total | 29a | 15a | 8839 | 1998–2017 |
HBeAg-negative patients | ||||
Lamivudine (LAM) | 9 | 8 | 1005 | 1999–2017 |
Adefovir (ADV) | 3 | 3 | 401 | 2003–2015 |
Telbivudine (TBV) | 2 | 2 | 242 | 2009–2014 |
Entecavir (ETV) | 4 | 3 | 470 | 2006–2017 |
Tenofovir disoproxil fumarate (TDF) | 3 | 3 | 544 | 2008–2016 |
Tenofovir alafenamide (TAF) | 1 | 1 | 285 | 2016 |
Pegylated interferon (PEG-IFN) | 6 | 2 | 375 | 2004–2016 |
Combination therapies | 7 | 2 | 525 | 2004–2016 |
Placebo (PLA) | 4 | 3 | 180 | 1999–2007 |
Total | 19a | 13a | 4046 | 1999–2017 |